(Total Views: 1305)
Posted On: 02/20/2019 1:40:35 PM
Post# of 30067
.jpg)
Coeptis has a new CEO. Former CEO now VP. Mike Rea of IDEA now on executive team. Dr. Paula Trezpacz Elto lead now on site.
MODI OBOCHI, PHD MBA
PRESIDENT & CHIEF EXECUTIVE OFFICER
High impact and visionary leader with 25+ years of global leadership experience and demonstrated successes leading high performing teams, growing revenues and shareholder value in Pharma and Biotech. Global leadership positions at QLT, Hospira, Pfizer and Baxter spanning general management, commercial, business development and R&D. Expanded Baxter’s $1 billion generic injectable business as the Global VP for Pharmaceuticals Injectables; developed differentiated sterile injectable products for Pfizer; as Head of Global Strategic Marketing at Hospira, accelerated profitable portfolio growth of Hospira’s $3.5 billion sterile injectable pharmaceuticals (including 60 product launches), resulting in the acquisition of Hospira by Pfizer for all cash deal of $15 billion.
Major improvement given his pharma experience and maintaining to former CEO, who was still proven in financing is great news.
Here's hoping the raise, or some new plan is effective soon.
http://coeptispharma.com/executive-team/
MODI OBOCHI, PHD MBA
PRESIDENT & CHIEF EXECUTIVE OFFICER
High impact and visionary leader with 25+ years of global leadership experience and demonstrated successes leading high performing teams, growing revenues and shareholder value in Pharma and Biotech. Global leadership positions at QLT, Hospira, Pfizer and Baxter spanning general management, commercial, business development and R&D. Expanded Baxter’s $1 billion generic injectable business as the Global VP for Pharmaceuticals Injectables; developed differentiated sterile injectable products for Pfizer; as Head of Global Strategic Marketing at Hospira, accelerated profitable portfolio growth of Hospira’s $3.5 billion sterile injectable pharmaceuticals (including 60 product launches), resulting in the acquisition of Hospira by Pfizer for all cash deal of $15 billion.
Major improvement given his pharma experience and maintaining to former CEO, who was still proven in financing is great news.
Here's hoping the raise, or some new plan is effective soon.
http://coeptispharma.com/executive-team/
(5)
(0)
